Genesis Therapeutics

Genesis Molecular AI's current partner pipeline identifies Gilead's use of GEMS against three initial hard-to-drug targets in a collaboration started in 2024, with AI researchers and drug-discovery teams working across partnered programs.

Incyte and Genesis report expanding their ongoing GEMS collaboration in May 2026 following initial program results, broadening AI deployment and adding at least five targets while arranging proprietary experimental-data sharing for model training.

Genesis applies AI to small-molecule drug discovery programs, with real pharmaceutical development activity but limited broad deployment.

Genesis Molecular AI describes Pearl protein-ligand 3D structure prediction trained with proprietary physics-based synthetic data and program-specific fine-tuning. This named model and training approach is distinct from the existing general structure-based drug-discovery description.

Genesis develops AI and molecular modeling systems for structure-based small-molecule discovery.

Genesis develops AI and molecular modeling systems for structure-based small-molecule discovery.

Genesis' official news archive documents its $200 million August 2023 investment, and transaction counsel Ropes & Gray confirms completion of the oversubscribed Series B. This dated financing is independent of existing computational-chemistry and research-team capability.

Genesis combines computational chemistry, ML and drug-development expertise in a specialized research organization.

Genesis combines computational chemistry, ML and drug-development expertise in a specialized research organization.

Genesis describes Pearl's diffusion architecture with equivariant neural networks trained on physics-based synthetic data, reinforcement learning with physics-based rewards, and multimodal learning that combines 3D structures with bioassay data.

ML and molecular modeling skills transfer to adjacent biotech roles, with substantial chemistry and drug-discovery domain dependence.

ML and molecular modeling skills transfer to adjacent biotech roles, with substantial chemistry and drug-discovery domain dependence.